ArticlemAbs2025
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb.
Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Mapping the membrane-enriched proteome of recombinant Chinese hamster ovary cells following induction of endoplasmic reticulum stress.Biotechnology letters · 2026Article
- Effects of feeding strategies on culture performance and product quality in NISTCHO.NPJ systems biology and applications · 2026Article
- Proteasome Inhibition Amplifies Endoplasmic Reticulum (ER) Stress Responses: Comparative Proteomics of Chinese Hamster Ovary Cell Lines.Biomolecules · 2026Article
- Process development for production of non-originator NISTmAb from CHO and NS0 cell lines.mAbs · 2025Article
- NIST Biomanufacturing Reference Materials: Development, Applications, and Impact.Bridge (Washington, D.C. : 1969) · 2025Article
- Development and Characterization of the NISTCHO Reference Cell Line.Biotechnology journal · 2025Article
- NS0 and CHO cell lines generate distinct quality profiles for non-originator NISTmAbs.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NISTCHO is a Chinese hamster ovary (CHO) cell line expressing the same amino acid sequences as the heavy and light chains of the National Institute of Standards and Technology (NIST) monoclonal antibody [Reference Material (RM) 8671 NISTmAb]. NISTCHO was generated by MilliporeSigma to be developed by NIST as a RM to support biomanufacturing research and innovation, method development and qualification, and pre-competitive research collaboration. The RM cell line, denoted as RM 8675 NISTCHO, Clonal CHO-K1 Cell Line Producing cNISTmAb, is of interest to the biopharmaceutical and biomanufacturing industries, regulatory and government agencies, and academic institutions. In contrast to other NIST RMs, however, which are typically discrete and finite, the NISTCHO is a living RM that can be propagated, expanded, and used repeatedly to express the non-originator NISTmAb product, cNISTmAb. Therefore, a uniform naming convention should be adopted by the user community to best track the origins of materials (the cell line and products) used in studies derived from the RM 8675 NISTCHO. Here, we provide a naming convention for the derivatives of the RM 8675 NISTCHO and the cNISTmAb produced by these NISTCHO derivatives and recommend these naming conventions for adoption by the scientific community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.